| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Myriad Genetics has a current Overall Rating of D (Negative). | 7 |
$25 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for MYGN. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: MYRIAD GENETICS -- MYGN | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: IDIX , ITMN , ISIS , MYGN , ORXE , OSIP -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| MYGN: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | MYRIAD GENETICS INC (MYGN=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of MYRIAD GENETICS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
1.48% Nasdaq 
Research Reports
